Raymond James & Associates Biocryst Pharmaceuticals Inc Transaction History

Raymond James & Associates

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$10.5 - $14.2 $154,707 - $209,222	14,734 New	14,734 $169,000
Q4 2021 Feb 08, 2022	SELL	$11.18 - $15.46 $204,403 - $282,655	-18,283 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$14.21 - $17.65 $12,632 - $15,690	-889 Reduced 4.64%	18,283 $263,000
Q2 2021 Aug 11, 2021	BUY	$9.5 - $17.24 $182,134 - $330,525	19,172 New	19,172 $303,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.